Genmab — April 2023
-
-
-
Nu giver det hele pludselig mening efter ar Sukker skar ud i pap, at det er lenalidomid der linkes til dara og ikke et eller andet giftstof. Spændende, hvis effekten af konjugatet er 100 gange større end dara og len, eller endda kombien dara/len. Og så skal der kun bruges en brøkdel af mængden af len ift normalt. Og endvidere “less toxic” end dara/len kombien.
-
De laver også denne: "In db/db mice and diabetic rhesus monkeys, TE-8105 could reduce elevated blood glucose for longer periods and at lower dosage than semaglutide" og "In diet-induced obese (DIO) mice, TE-8105 could reduce body weight more effectively than semaglutide in a q4d regimen
-
免疫功坊股份有限公司Immunwork
Immunwork, Inc. located in Taipei, Taiwan was founded in October 2014.After a corporate reorganization in November 2019, Immunwork is now a wholly owned subsidiary of T-E Pharma Holding, incorporated in Cayman Island. Immunwork focuses on the research and development of a class of new drugs, which are created based on our proprietary “T-E pharmaceuticals” technology platform. The first group of new drugs is for treating several types of cancer, diabetes, obesity, fatty liver diseases, and pathological blood clots.
免疫功坊股份有限公司 IMMUNWORK (www.immunwork.com)
-
The Clinical Landscape Of ADCs In 2023: Diverse Technologies, Narrow Target
Antibody-drug conjugates (ADCs) are a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the potency of...
(www.clinicalleader.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind